VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Carlyle Secured Lending
CGBD
$1.01B
| $350K | 0.21% |
24,040
-566
| -2% | -$8.24K |
|
152
BridgeBio Pharma
BBIO
$10.2B
| $350K | 0.21% |
20,345
-11,903
| -37% | -$205K |
|
153
Exelixis
EXEL
$10.2B
| $350K | 0.21% |
18,297
-729
| -4% | -$13.9K |
|
154
Hercules Capital
HTGC
$3.49B
| $349K | 0.21% |
23,603
-2,773
| -11% | -$41K |
|
155
Barings BDC
BBDC
$987M
| $346K | 0.21% |
44,163
-535
| -1% | -$4.19K |
|
156
Ionis Pharmaceuticals
IONS
$9.76B
| $345K | 0.2% |
8,418
+374
| +5% | +$15.3K |
|
157
Zai Lab
ZLAB
$3.42B
| $344K | 0.2% |
12,423
+3,646
| +42% | +$101K |
|
158
Invesco Senior Income Trust
VVR
$555M
| $344K | 0.2% |
89,336
+70,596
| +377% | +$272K |
|
159
Neurocrine Biosciences
NBIX
$14.3B
| $344K | 0.2% |
3,647
+1,062
| +41% | +$100K |
|
160
Legend Biotech
LEGN
$6.66B
| $344K | 0.2% |
4,982
-956
| -16% | -$66K |
|
161
Amgen
AMGN
$153B
| $343K | 0.2% |
1,546
+398
| +35% | +$88.4K |
|
|
RETA
162
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $343K | 0.2% |
3,362
+488
| +17% | +$49.8K |
|
163
Theravance Biopharma
TBPH
$703M
| $342K | 0.2% |
33,009
+5,537
| +20% | +$57.3K |
|
164
PennantPark Floating Rate Capital
PFLT
$1.02B
| $342K | 0.2% |
32,078
+7,158
| +29% | +$76.2K |
|
|
DCPH
165
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $341K | 0.2% |
24,233
+4,840
| +25% | +$68.1K |
|
166
Acadia Pharmaceuticals
ACAD
$4.26B
| $341K | 0.2% |
14,235
-5,285
| -27% | -$127K |
|
167
Apellis Pharmaceuticals
APLS
$3.55B
| $340K | 0.2% |
3,730
-2,117
| -36% | -$193K |
|
168
Gilead Sciences
GILD
$143B
| $340K | 0.2% |
4,408
+921
| +26% | +$71K |
|
169
Ascendis Pharma
ASND
$12.5B
| $339K | 0.2% |
3,802
+1,266
| +50% | +$113K |
|
170
Harmony Biosciences
HRMY
$2.07B
| $338K | 0.2% |
9,609
+4,361
| +83% | +$153K |
|
|
ITCI
171
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $338K | 0.2% |
5,336
-504
| -9% | -$31.9K |
|
172
Aurinia Pharmaceuticals
AUPH
$1.63B
| $337K | 0.2% |
34,850
-31,098
| -47% | -$301K |
|
173
United Therapeutics
UTHR
$18.1B
| $335K | 0.2% |
1,519
+406
| +36% | +$89.6K |
|
174
BioNTech
BNTX
$27B
| $334K | 0.2% |
3,097
+1,442
| +87% | +$156K |
|
175
Ironwood Pharmaceuticals
IRWD
$188M
| $331K | 0.2% |
31,097
+6,259
| +25% | +$66.6K |
|